#Osteoarthritis #ClinicalTrials #Research #KnowledgeTranslation #DrugDevelopment To view or add a comment, sign in The evidence for Arthramid 2.5% iPAAG is growing, and its redefining what long-term success looks like
Competitive athletes should also be aware that BPC-157 is listed by USADA as a prohibited experimental peptide under the WADA S0 Unapproved Substances category
Monitoring fluid intake and limb elevation can alleviate discomfort
The MIC compounds in lipotropic injections help support the liver, which plays a key role in fat metabolism
Potential side effects may include injection-site redness, swelling, bruising, itching, tenderness, small lumps, headache, fatigue, nausea, appetite changes, abdominal discomfort, stool changes, dizziness, altered sleep, mood changes, or feeling off. Allergic or immune reactions are also possible, and the FDA has specifically raised concerns about immunogenicity and peptide-related impurities in compounded BPC-157
Best for isolated tendon or ligament work, gut-lining repair, or specific injury recovery